Narendra D. Lalwani, Ph.D., FAHA, DABT
2016
In 2016, Narendra D. Lalwani, Ph.D., FAHA, DABT earned a total compensation of $695.7K as Executive Vice President, Research and Development and Chief Operating Officer at Esperion Therapeutics, a 78% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $85,000 |
|---|---|
| Option Awards | $208,734 |
| Salary | $390,000 |
| Other | $12,000 |
| Total | $695,734 |
DABT received $390K in salary, accounting for 56% of the total pay in 2016.
DABT also received $85K in non-equity incentive plan, $208.7K in option awards and $12K in other compensation.
Rankings
In 2016, Narendra D. Lalwani, Ph.D., FAHA, DABT's compensation ranked 9,909th out of 14,075 executives tracked by ExecPay. In other words, DABT earned more than 29.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 9,909 out of 14,075 | 30th |
Division Manufacturing | 3,825 out of 5,486 | 30th |
Major group Chemicals And Allied Products | 1,340 out of 1,900 | 30th |
Industry group Drugs | 1,068 out of 1,543 | 31st |
Industry Pharmaceutical Preparations | 839 out of 1,173 | 29th |
Source: SEC filing on April 13, 2018.
DABT's colleagues
We found four more compensation records of executives who worked with Narendra D. Lalwani, Ph.D., FAHA, DABT at Esperion Therapeutics in 2016.